FBXO5 and neoplasm: Next, the differential analysis of FBXO5 expression in each tumor type were examined in accordance with the age of patients, which suggested that patients aged > 60 years old had lower expression levels of FBXO5 compared with those aged ≤ 60 years old in several tumor types including BRCA, ESCA, HNSC, LIHC, and THYM, while patients aged > 60 years old with OV had higher FBXO5 expression than those aged ≤ 60 years old (Figure 3C).